JP2016535270A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535270A5
JP2016535270A5 JP2016533958A JP2016533958A JP2016535270A5 JP 2016535270 A5 JP2016535270 A5 JP 2016535270A5 JP 2016533958 A JP2016533958 A JP 2016533958A JP 2016533958 A JP2016533958 A JP 2016533958A JP 2016535270 A5 JP2016535270 A5 JP 2016535270A5
Authority
JP
Japan
Prior art keywords
tumor
proteins
protein
protein kinase
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535270A (ja
Filing date
Publication date
Priority claimed from GBGB1314485.2A external-priority patent/GB201314485D0/en
Application filed filed Critical
Publication of JP2016535270A publication Critical patent/JP2016535270A/ja
Publication of JP2016535270A5 publication Critical patent/JP2016535270A5/ja
Pending legal-status Critical Current

Links

JP2016533958A 2013-08-13 2014-08-13 膵臓癌に関連する物質及び方法 Pending JP2016535270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1314485.2 2013-08-13
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer
PCT/GB2014/052475 WO2015022530A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2016535270A JP2016535270A (ja) 2016-11-10
JP2016535270A5 true JP2016535270A5 (enExample) 2017-12-28

Family

ID=49262110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533958A Pending JP2016535270A (ja) 2013-08-13 2014-08-13 膵臓癌に関連する物質及び方法

Country Status (7)

Country Link
US (1) US20160195536A1 (enExample)
EP (1) EP3033624A2 (enExample)
JP (1) JP2016535270A (enExample)
CN (1) CN105637367A (enExample)
CA (1) CA2920946A1 (enExample)
GB (1) GB201314485D0 (enExample)
WO (1) WO2015022530A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044715A1 (en) * 2015-09-09 2017-03-16 Somalogic, Inc. Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
BR112019012441A2 (pt) * 2016-12-20 2020-04-14 Treat4Life Ab método para determinar mutações braf e proteína braf do tipo selvagem por espectrometria de massa
EP3811081A1 (en) * 2018-06-21 2021-04-28 Universiteit Utrecht Holding B.V. Method for monitoring kinase activity in a sample
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
WO2022154037A1 (ja) * 2021-01-14 2022-07-21 公立大学法人福島県立医科大学 がんの予後バイオマーカー

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
DE60239962D1 (de) 2001-08-14 2011-06-16 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
CA2726531A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
CA2750818A1 (en) * 2009-01-27 2010-08-05 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
WO2011088030A1 (en) * 2010-01-15 2011-07-21 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
US20120309706A1 (en) * 2010-02-01 2012-12-06 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
EP2561368B1 (en) * 2010-04-19 2017-08-02 Biomarker Strategies, LLC. Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
CA2800023A1 (en) * 2010-06-01 2011-12-08 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject
ES2611479T3 (es) * 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
CA2838736A1 (en) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer

Similar Documents

Publication Publication Date Title
JP2016535270A5 (enExample)
Chen et al. Prognostic fifteen-gene signature for early stage pancreatic ductal adenocarcinoma
JP6600637B2 (ja) 膵臓がんを決定するための方法、アレイおよびそれらの使用
Alaiya et al. Clinical cancer proteomics: promises and pitfalls
CN106662578B (zh) 用于检测食物变态反应的肽、试剂和方法
Huettenhain et al. N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications
CA2974775C (en) Biomarkers for pancreatic cancer
Cao et al. Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts
KR20140040118A (ko) 췌장암의 존재를 결정하기 위한 방법, 어레이 및 그의 용도
JP2010522875A5 (enExample)
CN103038642B (zh) 方法、阵列及其用途
Zhang et al. Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ‐Based Quantitative Proteomic Analysis
Jain Innovations, challenges and future prospects of oncoproteomics
CN110716050A (zh) 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法
JP2016519767A5 (enExample)
Loch et al. Use of high density antibody arrays to validate and discover cancer serum biomarkers
Park et al. Evolutionary identification of affinity peptides for the detection of sepsis biomarker procalcitonin
Zhou et al. Oncoproteomics: trials and tribulations
EP4314347A1 (en) Proteogenomic analysis of non-small cell lung cancer
Panis et al. How can proteomics reach cancer biomarkers?
KR102343240B1 (ko) 대장암 환자에서 세툭시맙에 대한 내성 예측용 바이오마커 조성물
US20210080465A1 (en) SH2 domain-based prognostic biomarker for chronic lymphocytic leukemia
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
US20190120834A1 (en) Marker sequences for rheumatoid arthritis
Jeon et al. C-reactive protein as a parameter for defining normal blood samples in identification and evaluation of serological biomarkers